Cover Image

Nirmatrelvir, a novel medication for COVID-19 treatment

Saved in:

Bibliographic Details
Main Authors:	Mohammad Reza Hajian (Author), Hamid Reza Jahantigh (Author), Shahrzad Alimohammadi (Author), Zahra Mojtahedi (Author), Neda Kianpour (Author), Majid Foroutan (Author)
Format:	Book
Published:	Society of Diabetic Nephropathy Prevention, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
by: Alireza Pouramini, et al.
Published: (2022)

Relapses or de-novo IgA nephropathy following COVID-19 vaccination; a narrative review
by: Masoud Hafizi, et al.
Published: (2023)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022)

Kidney in chronic uncontrolled hypertension; mind the dual pathology
by: Dorsa Jahangiri, et al.
Published: (2023)

Crescentic glomerulonephritis in a man with a history of methamphetamine abuse; a possible cause for concern
by: Dorsa Jahangiri, et al.
Published: (2023)

Autophagy and treatment of patients with COVID-19; which drugs target the autophagy pathway?
by: Elahe Aleebrahim-Dehkordi, et al.
Published: (2022)

Population Pharmacokinetics and Dosing Regimen Analysis of Nirmatrelvir in Chinese Patients with COVID-19 Infection
by: Zhang R, et al.
Published: (2024)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023)

Managing nirmatrelvir/ritonavir during COVID-19: pharmacists' experiences from the Perak state of Malaysia
by: Chee Tao Chang, et al.
Published: (2022)

Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023)

Chronic dehydration-related nephropathy; an under-recognized cause of renal failure in tropics
by: Dorsa Jahangiri, et al.
Published: (2023)

A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir
by: Jiantao Zheng, et al.
Published: (2023)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
by: Raymond K. Hau, et al.
Published: (2022)

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
by: Sheng En Alexius Matthias Soh, et al.
Published: (2024)

Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies
by: Michael Peluso, et al.
Published: (2022)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
by: Aili Lu, et al.
Published: (2023)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022)

Systemic lupus erythematosus following SARS-CoV-2 vaccination; a review of literature
by: Leila Mahmoudnia, et al.
Published: (2023)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023)

Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report
by: Hassan Almarhabi, et al.
Published: (2024)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
by: Eun-Jeong Kwon, et al.
Published: (2022)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
by: Jinhua Huang, et al.
Published: (2022)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024)

Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
by: Nan Shang, et al.
Published: (2024)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023)

Comparison of the effects of pramipexole and gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis
by: Sepideh Hajian, et al.
Published: (2020)

Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
by: Ye Qiu, et al.
Published: (2024)

Identifying the roles of medical librarians in COVID-19 crisis in Iran
by: Zahra Kazempour, et al.
Published: (2021)

Assessment of Hospital Risks for Occupational Safety of Healthcare Staff against Covid-19 Using FMEA Method and Multi-Criteria Decision-Making Methods (Case study: Department of Infectious Diseases of Bu-Ali hospital in Zahedan)
by: Neda Vahedi nezhad, et al.
Published: (2021)

Perceived challenges caused by Covid-19 outbreak in students of medical sciences
by: Nayereh Baghcheghi, et al.
Published: (2022)

Herbal medicines in the treatment of coronavirus disease 2019 (COVID-19)
by: Audrey Tolouian, et al.
Published: (2021)

Modeling of Hospitalization Time to Recovery of Patients with COVID-19 in Hospitals of Golestan University of Medical Sciences
by: Alireza Heidari, et al.
Published: (2023)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023)